Precision bioactives for selective oral microbiome modulation
Trilliome offers a pipeline of plant-derived bioactives designed to modulate the oral microbiome and prevent gingivitis without broad-spectrum antimicrobial sterilization. These precision prebiotics/postbiotics nourish health-associated species while suppressing pathobionts, ensuring sustainable and clinically de-risked solutions for oral care.
Overview
Trilliome presents a groundbreaking approach to oral care with its precision bioactives targeting the oral microbiome. Unlike traditional antimicrobials that indiscriminately kill bacteria, these plant-derived bioactives selectively nourish beneficial oral species while suppressing harmful pathobionts. This method prevents gingivitis by maintaining microbial balance without disturbing the mouth's natural defenses. The solution is sustainable, using bioactives sourced from upcycled plant side-streams, and is ready for translation into mass-market oral care products.
Technical specifications
Our bioactives act as precision prebiotics/postbiotics, providing targeted nourishment to health-associated oral microbiome species. Key features include being zinc-free, containing no live probiotics, and maintaining excellent matrix stability. The formulation is designed to seamlessly integrate into existing oral care products such as toothpaste or mouthwash, offering a unique advantage in product development. Initial validation through first-in-human data and advanced ex-vivo models supports their efficacy.
Technology readiness level
Currently at TRL 5, Trilliome's bioactives have been validated in human trials and are progressing through further phases of formulation and safety testing. The technology is on track for scaling and market launch, with plans to achieve Self-GRAS status by Q4 2026, supported by a robust partnership model that includes joint patent opportunities and production protocols.
About Trilliome
Trilliome is a Swiss biotechnology company that develops precision microbiome ingredients aimed at healthy aging. Utilizing an AI-driven discovery platform, the company identifies and validates plant-derived bioactives designed to modulate gut microbial networks. Its lead product, TRI-01, is engineered to increase gut-resident bacteria associated with anti-inflammatory and brain-protective metabolites, targeting key features of aging such as cognitive decline, mood disturbances, and systemic inflammation. Trilliome operates at the intersection of biotechnology and nutrition, focusing on scalable, science-backed solutions for the B2B functional food and supplement sectors. By upcycling plant and fruit waste into therapeutic ingredients, the company combines medical-grade microbiome science with circular sustainability practices to improve health outcomes and longevity. Their approach is validated through human-relevant ex-vivo data and ongoing clinical development, aiming to restore the gut-brain-immune axis. The company has received significant recognition, including awards from EIT Food, Probiota, and the Aging Research and Drug Discovery conference, highlighting its innovative position in the longevity space.
delivered to your inbox.